the highest mcv and mcv increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia : hodgkin 's disease treated with mopp and radiotherapy , and multiple myeloma and ovarian cancer treated with melphalan .
C0026764
multiple myeloma
C0025241
melphalan